Aurobindo Pharma buys four biosimilar drugs from TL Biopharmaceutical

Industry Reports
Typography

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.

The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising. Regulatory filing for these products is intended in the period 2020-22. 

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers

This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline. Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana which would be ready by Q2, FY 18

Commenting on the strategic alliance, Mr. N. Govindarajan, Managing Director of Aurobindo Pharma Limited said: "We are impressed with TL's product developement as these are  developed to the highest standards of biosimilarity. This acquisition is in-line with our strategy of investing in complex products and is on important first step towards establishing Aurobindo's global biosimilar's portfolio.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) , headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals,Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Sign up via our free email subscription service to receive notifications when new information is available.
captcha 

Market Movers

Rogers Corporation

NYQ : ROG - 16 Oct, 4:02pm
139.53
+2.83 (+2.07%) After Hours:
Open 137.60 Mktcap 2.54B
High 139.74 52wk Hight 139.74
Low 137.05 52wk Low 51.98
Vol 86121 Avg Vol 120528
Eps 5.55 P/e 33.70
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 16 Oct, 4:04pm
6.52
-0.01 (-0.11%) After Hours:
Open 6.51 Mktcap 20.57B
High 6.53 52wk Hight 6.99
Low 6.47 52wk Low 4.36
Vol 3.84M Avg Vol 5.41M
Eps 0.49 P/e 11.99
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 16 Oct, 4:00pm
63.34
-0.05 (-0.08%) After Hours:
Open 63.49 Mktcap 172.75B
High 63.73 52wk Hight 66.80
Low 63.26 52wk Low 58.29
Vol 7.45M Avg Vol 7.72M
Eps 3.87 P/e 34.24
Currency: USD

Johnson & Johnson

NYQ : JNJ - 16 Oct, 4:00pm
136.12
-0.31 (-0.23%) After Hours:
Open 136.45 Mktcap 365.35B
High 137.26 52wk Hight 137.52
Low 135.54 52wk Low 109.32
Vol 5.12M Avg Vol 5.26M
Eps 7.18 P/e 22.88
Currency: USD

Pfizer, Inc.

NYQ : PFE - 16 Oct, 4:00pm
35.98
-0.36 (-0.99%) After Hours:
Open 36.35 Mktcap 59.45B
High 36.48 52wk Hight 36.60
Low 35.88 52wk Low 29.83
Vol 13.58M Avg Vol 17.16M
Eps 2.56 P/e 26.26
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 16 Oct, 3:37pm
13.81
+0.06 (+0.44%) After Hours:
Open Mktcap
High 52wk Hight 16.29
Low 52wk Low 13.12
Vol 0 Avg Vol 3888
Eps P/e
Currency: USD